CSIMarket Company Name, Ticker, Competitors, else..
 
Novavax inc   (NVAX)
Other Ticker:  
 
 
Price: $7.2100 $0.32 4.644%
Day's High: $7.265 Week Perf: -4.38 %
Day's Low: $ 6.80 30 Day Perf: -4.63 %
Volume (M): 4,104 52 Wk High: $ 76.77
Volume (M$): $ 29,591 52 Wk Avg: $23.10
Open: $6.92 52 Wk Low: $5.61



 Market Capitalization (Millions $) 621
 Shares Outstanding (Millions) 86
 Employees 370
 Revenues (TTM) (Millions $) 1,359
 Net Income (TTM) (Millions $) -1,155
 Cash Flow (TTM) (Millions $) -947
 Capital Exp. (TTM) (Millions $) 100

Novavax Inc
Novavax Inc.
is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent infectious diseases.
The company is headquartered in Gaithersburg, Maryland, and was founded in 1987.
Novavax's focus is on developing novel recombinant protein nanoparticle vaccines using its proprietary technology platform, Matrix-M.
Matrix-M is a proprietary saponin adjuvant that stimulates the immune system and enhances the efficacy of vaccines.
Novavax has used this adjuvant to develop vaccines for a variety of infectious diseases, including influenza, respiratory syncytial virus (RSV), COVID-19, and Ebola.
Novavax's lead product candidate, NVX-CoV2373, is a COVID-19 vaccine that uses Matrix-M to enhance the immune response to the SARS-CoV-2 spike protein.
The vaccine is administered in two doses, 21 days apart, and has shown high levels of efficacy in clinical trials conducted in the UK and South Africa.
Novavax has partnered with several organizations to develop and distribute its vaccines globally.
In the US, the company has received funding from the US Department of Defense, the National Institutes of Health, and the Coalition for Epidemic Preparedness Innovations (CEPI).
Overall, Novavax Inc is a biotechnology company that is pioneering the use of recombinant protein nanoparticle vaccines, with its proprietary Matrix-M technology.
The company has a strong pipeline of vaccines and partnerships with several organizations for global distribution.


   Company Address: 21 Firstfield Road Gaithersburg 20878
   Company Phone Number: 268-2000   Stock Exchange / Ticker: NASDAQ NVAX
   NVAX is expected to report next financial results on August 07, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Agilent Technologies Inc

Reasonable result at Agilent Technologies Inc over the financial second quarter of 2023

Agilent Technologies Inc, a Biotechnology and Pharmaceuticals company has released its financial results for the three months ending April 30, 2023. The company's revenue increased by 6.845% to $1.72 billion as compared to $1.61 billion on a year-over-year basis. Meanwhile, the company's profitability showed significant improvement, with profits rising 12.09% to $1.02 from $0.91 in the prior year reporting season.
However, there was a decrease in revenue by -2.221% from $1.76 billion in the preceding period, and profits also fell by -14.29% from $1.19 per share. Despite these reductions, earnings rose by 10.22% from net earnings of $274.000 million reported in the second quarter of the 2023 earnings season a year ago.
Steris Plc

The Biotechnology and Pharmaceuticals company has failed to turn into profitability despite the epic Surge in revenue in the fourth quarter of 2023

Steris Plc, a leading biotechnology and pharmaceuticals company, has announced a significant increase in revenue for the most recent fiscal period. The company reported a year-on-year revenue rise of 311.172% to $2.94 billion, which is an impressive figure. However, the company slipped into a net loss of $-0.60. This news is significant and has caused some concern among investors and stakeholders.
Compared to the preceding quarter, the income per share fell from $0.56 per share. On the other hand, revenue doubled by a substantial 322.827% from $696.24 million. In the fourth quarter of 2023, Steris Plc posted a net loss of $-90.386 million, as opposed to the net proceeds of $73.623 million recorded in the same quarter a year before. This decline in profits is concerning and indicates a downward trend.
Burzynski Research Institute Inc

The emerging corporation from the Biotechnology and Pharmaceuticals market the Burzynski Research Institute Inc issued the fourth quarter of 2023, results

As a journalist who closely follows the financial performance of various corporations, I find the latest results from Burzynski Research Institute Inc quite intriguing. This small biotech and pharmaceutical firm has reported an operating deficit of $-0.215998 million for the fourth quarter of 2023. While the company has not yet revealed its revenue figures, it is worth comparing these results with the corresponding period from the previous year.
In the fourth quarter of 2022, Burzynski Research Institute Inc had already reported an operating deficit of $-0.131272 million. The fact that the shortfall has further expanded to $-0.216 million in the same quarter of 2023 suggests that the company is going through a turbulent period. However, it's important to note that many businesses face such choppy phases while they try to establish prosperous revenue sources.
Immunovant Inc

The Biotechnology and Pharmaceuticals company announced Revenue of $4.098 million, in the financial fourth quarter of 2023

Immunovant Inc, a clinical stage biopharmaceutical company, has reported their financial results for the fiscal period ending March 31, 2023. According to the report, the company generated revenue of $4.098 million, which is a positive sign.
However, the company also reported a net loss of $59.432 million for the same period, higher than the previous year's loss of $47.171 million. The net loss per share has worsened from $1.43 in the previous fiscal year to $1.71 in this fiscal year, indicating that the company is facing some financial challenges.
Replimune Group Inc

Replimune Group Inc announced operating loss of $-52.995 million, in the fourth quarter of 2023 financial report

Replimune Group Inc is a biotechnology company that focuses on developing cancer therapies based on the use of oncolytic viruses. The company's goal is to develop a range of therapies that can be used in combination with other cancer treatments to improve patient outcomes.
The recent earnings announcement by Replimune Group Inc has raised concerns among investors, who are worried about the company's current financial situation. The $52.995 million operating loss for the most recent fiscal period is a cause for concern, particularly as the company is expected to report further losses in the coming months.





 

Novavax Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071